Table 2.

Prevalence and severity of HSRs to rituximab.

References	Types, clinical features, and severity
Brennan et al., 2009 n = 14 patients	Clinical presentations	Approximately 57% cutaneous, 50% cardiovascular, 50% respiratory, 30% fever, 30% throat, 20% gastrointestinal, and 30% neurological reactions
	Severity	Grade I: 25%, Grade II: 50%, Grade III: 30%
van Vollenhoven et al., 2013 n = 3194 patients	-Acute infusion related reactions: 77% of patients
Levin et al., 2017 n = 67 patients	Incidence of reactions in relation to the number of infusions	63% of reactions during 1st infusion, 9% during 2nd infusion, 15% during cycles 3–10, 7% during cycles 11–20, 6% during cycles 20–53
	Clinical presentations	63% cutaneous reactions, 45% generalized pruritis, 21% flushing, 16% hives
	Severity	Grade 1A: 18%, Grade 1B: 9%, Grade 2: 61%, Grade 3: 10%, Grade 4: Less than 1%
Isabwe et al., 2018 n = 52 patients	Reactions	Acute infusion reactions: 20-50% Type I reactions: 63% Cytokine-release reactions: 13% Mixed reactions: 21% Delayed reactions: 3%
	Severity	Grade I: 13%, Grade II: 60%, Grade III: 29%
Görgülü et al., 2019 n = 24 patients	Reactions (Based on Isabwe et al., 2018)	Type I (IgE/non-IgE): 46% Cytokine-release reaction: 12.5% Mixed reactions: 41.5%
	Clinical presentations	Cutaneous symptoms 92%, Respiratory symptoms 88%, Cardiovascular symptoms 67%, Gastrointestinal symptoms 55%, Neurologic/muscular symptoms 29%, Fever (≥38.3°C) 46%
	Severity	Grade I: 0%, Grade II: 63%, Grade III: 37%